Pancragen

A tetrapeptide bioregulator associated with pancreatic tissue and glucose regulation in Russian studies.

Pancragen is classified as a short peptide bioregulator. Its current development status is: preclinical / russian clinical use. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.

The Peptide Institute tracks Pancragen because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.